title: Proton pump inhibitors and fracture risk: response to comments.
authors.affiliation: Jiangsu Center for Safety Evaluation of Drugs, School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, 210009, China.
authors.forename: B
authors.initials: B
authors.lastname: Zhou
authors.affiliation: Jiangsu Center for Safety Evaluation of Drugs, School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, 210009, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Huang
authors.affiliation: Jiangsu Center for Safety Evaluation of Drugs, School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, 210009, China.
authors.forename: H
authors.initials: H
authors.lastname: Li
authors.affiliation: Jiangsu Center for Safety Evaluation of Drugs, School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, 210009, China.
authors.forename: W
authors.initials: W
authors.lastname: Sun
authors.affiliation: Jiangsu Center for Safety Evaluation of Drugs, School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, 210009, China. jansens2004@sina.com.
authors.forename: J
authors.initials: J
authors.lastname: Liu
mesh_terms: D050723:Fractures, Bone; D006801:Humans; D054328:Proton Pump Inhibitors; D012306:Risk
chemical_list: D054328:Proton Pump Inhibitors